bluebird bio (BMV:BLUE *) - 주가, 뉴스 및 분석

BLUE * 주식 개요

는 미국에서 중증 유전 질환 치료를 위한 유전자 치료제를 연구, 개발 및 상용화하는 생명공학 회사입니다. 자세한 내용

BLUE * 기본 분석
눈송이 점수
가치 평가	4/6
미래 성장	2/6
과거 실적	0/6
재무 상태	0/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 94.9% 에서 거래

수익은 연간 41.53% 증가할 것으로 예상됩니다.

위험 분석

지난 1년 동안 주주가 크게 희석되었습니다.

cash runway 경력이 1년 미만입니다.

마이너스 주주 지분

주식은 유동성이 매우 낮습니다

+ 3 더 많은 위험

bluebird bio, Inc. 경쟁사

Generation Bio

NasdaqGS:GBIO

US$96.2m

BioAtla

NasdaqGM:BCAB

US$80.3m

Coya Therapeutics

NasdaqCM:COYA

US$106.6m

X4 Pharmaceuticals

NasdaqCM:XFOR

US$60.1m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 bluebird bio
과거 주가
현재 주가	US$10.00
52주 최고치	US$25.00
52주 최저치	US$9.50
베타	0.80
11개월 변경	0%
3개월 변경 사항	-17.36%
1년 변경 사항	n/a
33년 변화	-95.58%
5년 변화	-99.28%
IPO 이후 변화	-99.57%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	BLUE *	MX Biotechs	MX 마켓
7D	0%	0%	0%
1Y	n/a	0%	0%

수익률 대 산업: MX Biotechs 산업에 대해 BLUE * 의 성과를 판단하기에는 데이터가 부족합니다.

수익률 대 시장: MX 시장에 대해 BLUE * 의 성과를 판단하기에는 데이터가 부족합니다.

가격 변동성

Is BLUE *'s price volatile compared to industry and market?
BLUE * volatility
BLUE * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

안정적인 주가: BLUE * 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: 지난 1년간 BLUE * 의 변동성 변화를 확인하기에는 데이터가 충분하지 않습니다.

회사 소개

설립	직원	CEO	웹사이트
1992	282	Andrew Obenshain	www.bluebirdbio.com

는 미국에서 중증 유전 질환 치료를 위한 유전자 치료제를 연구, 개발 및 상용화하는 생명공학 회사입니다. 이 회사의 중증 유전 질환 치료 제품 후보로는 수혈 의존성 지중해빈혈 치료제 진테글로(ZYNTEGLO, 베티베글로겐 오토템셀), 겸상 적혈구 질환(SCD) 치료제 로보티베글로겐 오토템셀, 뇌부신백질이영양증 치료제 스카이소나(스카이소나 엘리발도진 오토템셀) 등이 있습니다. 임상 개발 프로그램에는 SCD 환자 치료에서 로보셀의 안전성과 효능을 평가하기 위한 HGB-205, HGB-206 및 HGB-210과 지중해빈혈 환자 치료에서 베티셀의 안전성과 효능을 평가하기 위한 HGB-204, HGB-205, HGB-207 및 HGB-212가 있습니다.

bluebird bio, Inc. 기본 사항 요약

bluebird bio 의 수익과 매출은 시가총액과 어떻게 비교하나요?
BLUE * 기본 통계
시가총액	Mex$1.49b
수익(TTM)	-Mex$6.07b
수익(TTM)	Mex$1.10b

1.4x

P/S 비율

-0.2x

P/E 비율

BLUE * 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
BLUE * 손익 계산서(TTM)
수익	US$53.12m
수익 비용	US$78.78m
총 이익	-US$25.66m
기타 비용	US$267.16m
수익	-US$292.82m

최근 보고된 수익

Sep 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.51
총 마진	-48.31%
순이익 마진	-551.25%
부채/자본 비율	-1,394.4%

BLUE * 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

BLUE * 주식 개요

보상

위험 분석

bluebird bio, Inc. 경쟁사

NasdaqGS:GBIO

US$96.2m

NasdaqGM:BCAB

US$80.3m

NasdaqCM:COYA

US$106.6m

NasdaqCM:XFOR

US$60.1m

가격 내역 및 성능

최근 뉴스 및 업데이트

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.80 loss in 3Q 2023)

New major risk - Revenue and earnings growth

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

Recent updates

Third quarter 2024 earnings released: US$0.31 loss per share (vs US$0.80 loss in 3Q 2023)

New major risk - Revenue and earnings growth

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

Chief Medical Officer recently sold Mex$176k worth of stock

Chief Medical Officer recently sold Mex$176k worth of stock

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

Less than half of directors are independent

Full year 2022 earnings released: US$3.39 loss per share (vs US$8.17 loss in FY 2021)

Less than half of directors are independent

Less than half of directors are independent

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Less than half of directors are independent

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

Less than half of directors are independent

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

Treasurer recently sold Mex$1.6m worth of stock

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

President recently sold Mex$1.9m worth of stock

Second quarter 2022 earnings released: US$1.36 loss per share (vs US$2.31 loss in 2Q 2021)

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

Chief Regulatory Officer recently sold Mex$140k worth of stock

Less than half of directors are independent

bluebird bio, Inc. Announces That the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee Recommends Approval of elivaldogene autotemcel (eli-cel) for the Treatment of Early Active Cerebral Adrenoleukodystrophy

FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy

Chief Commercial Officer recently sold Mex$226k worth of stock

Less than half of directors are independent

bluebird bio, Inc., Annual General Meeting, Jun 22, 2022

Bluebird Bio, Inc. Announces Executive Changes

bluebird bio, Inc. appoints Charlotte Jones-Burton as Class I director, effective March 7, 2022

bluebird bio, Inc. announced delayed annual 10-K filing

Less than half of directors are independent

bluebird bio, Inc. Announces Resignation of Jessica Whitten as Chief Accounting Officer and Principal Accounting Officer

Less than half of directors are independent

bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)

Insider recently sold Mex$80k worth of stock

bluebird bio, Inc. to Launch Both beti-cel and eli-cel for Patients in the U.S. in Mid-2022

Insider recently sold Mex$637k worth of stock

Less than half of directors are independent